LISBON, Portugal—New data from the FOURIER trial show that patients with higher baseline lipoprotein(a) levels may be more likely to derive benefit from PCSK9 inhibition. Michelle O’Donoghue, MD ...
Nivolumab in Patients With Relapsed or Refractory Hematologic Malignancy: Preliminary Results of a Phase Ib Study We conducted a nested case-control study among men age 40 to 59 years who gave blood ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback